Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Maternally-derived neutralizing antibodies reduce vaccine efficacy against porcine reproductive and respiratory syndrome virus infection

Patricia Renson a,d,e, Christelle Fablet b,e, Mathieu Andraud b,e, Valérie Normand f, Arnaud Lebret f, Frédéric Paboeuf c,e, Nicolas Rose b,e, Olivier Bourry c,e,*

a Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail (Anses), Unité Virologie Immunologie Porcines, BP 53, 22440 Ploufragan, France
b Anses, Unité Épidémiothèque, Santé et Bien-être, BP 53, 22440 Ploufragan, France
c Anses, Service de Production de Porcs Assainis et Expérimental, BP 53, 22440 Ploufragan, France
d Université Bretagne Loire, Cité Internationale, 1 Place Paul Ricœur, CS 54417, 35044 Rennes, France
e Union des Groupements de Producteurs de Viande de Bretagne (UGPVB), 104 Rue Eugène Pottier, 35065 Rennes Cedex, France
f Porc. Spective, Groupe vétérinaire Chêne Vert Conseil, ZA de Gohélève, 56920 Noyal-Pontivy, France

A R T I C L E   I N F O

Article history:
Received 1 February 2019
Accepted 14 June 2019
Available online 24 June 2019

Keywords:
PRRS virus
Modified live virus vaccine
Maternally derived antibody
Neutralizing antibody
IFNa
Interference

A B S T R A C T

Modified live virus (MLV) vaccines are commonly used to reduce the impact of porcine reproductive and respiratory syndrome (PRRS) but limited efficacy is achieved in field conditions. Here, we evaluated the impact of maternally-derived neutralizing antibodies (MDNAs) on vaccine efficacy after PRRS virus (PRRSV) challenge. Piglets with low (A−) or high (A+) MDNA levels derived from a commercial pig herd were moved to experimental facilities to be vaccinated (V+) or not (V−) with a PRRSV-1 MLV vaccine at 3 weeks of age (woa). Because of unexpectedly low vaccine detection in A−V+ piglets post-vaccination (pv), all V+ piglets received a second vaccination at 4 woa. Five weeks (W5) pv, piglets were inoculated with a PRRSV-1 field strain to evaluate vaccine protection, and were mingled 24 h later with non-inoculated piglets of similar immune status to assess viral transmission. Vaccine strain was detected at W2 pv in 69% and 6% of A−V+ and A+V+ piglets, and at W5 pv in 50% and 25% of A−V+ and A+V+ piglets, respectively. At W5 pv, 94% of A−V+ and 44% of A+V+ piglets seroconverted, with a significant IFNg response induction in the A−V+ group only. After challenge, compared to the V− inoculated group, viremia was 100-fold lower at 10 days post-infection in A−V+ whereas viremia was not significantly reduced in A+V+ piglets. A lower transmission rate was estimated for the A−V+ group: 0.15 [0.07–0.29] versus 0.44 [0.18–1.76] and 0.32 [0.14–0.68] for the A+V+ and V− groups, respectively. Investigations about the low vaccine strain detection after the first vaccination suggested a relationship between IFNa levels and vaccine strain detection in A−V+ piglets. We showed that MDNAs impair vaccine efficacy against PRRSV both in inoculated and contact piglets, probably by reducing vaccine replication. IFNa may also interfere with PRRSV vaccination. These new data could help improving vaccination protocols.

© 2019 Elsevier Ltd. All rights reserved.

1. Introduction

Porcine reproductive and respiratory syndrome (PRRS), caused by a small RNA virus, member of the Arteriviridae family [1], is one of the most costly diseases in swine production world-wide [2,3]. In Western Europe, PRRS virus 1 (PRRSV-1) is the main circulating PRRSV species. PRRSV infection is characterized by reproductive failure in sows and by respiratory disorders, growth retardation and increased mortality in growing pigs. PRRSV predisposes pigs to secondary infections associated with the porcine respiratory disease complex [4]. To limit the impact of PRRS, modified live virus (MLV) vaccines based on cell culture attenuated PRRSV strains are routinely used in gilts, sows and growing pigs, but control of PRRS in the field is still a challenge. Only partial protection is achieved, mainly limiting the clinical signs and lesions [5–7]. However, in experimental conditions, these vaccines provide good protection against PRRSV challenge in piglets, controlling the viremia in infected pigs and decreasing transmission to contact pigs [8,9]. Unlike to experimental conditions, in field conditions, vaccinated piglets are generally born to PRRSV infected, exposed or vaccinated sows since they are commonly vaccinated against PRRSV to prevent PRRSV circulation in farrowing units and improve farrowing
Consequently, high levels of maternally-derived antibodies (MDAs) against PRRSV are frequently detected in piglets vaccinated at weaning [11]. Among MDAs, maternally-derived neutralizing antibodies (MDNAs) can protect suckling piglets against PRRSV infection during their first weeks of life and prevent viremia in weaned piglets [12,13]. However, we recently demonstrated a negative impact of MDNAs on PRRSV vaccination in piglets vaccinated at 3 weeks of age (woa) with a PRRSV-1 MLV vaccine [14]. In this study, vaccine strain replication was impaired and both PRRSV antibody and IFN-γ-secreting cell production were inhibited for 4 weeks post-vaccination (pv) in piglets with high levels of MDNAs. This interference of MDNAs with post-vaccination immune response suggested weak protection against PRRSV infection of piglets vaccinated in presence of high MDNA levels that could explain the lower vaccine efficacy observed in the field. Previous studies reported that vaccination in piglets with high MDA levels had no impact on vaccine efficacy but neutralizing antibodies (NAs) were not considered [15]. In the present study, piglets were vaccinated in the presence of low or high MDNA levels and further challenged with a wild PRRSV-1 to assess the impact of MDNAs on the efficacy of PRRSV-1 MLV vaccination.

2. Material and methods

2.1. Animal selection and experimental design

The experiment was performed using 56 (Large White × Landrace) × Pietrain piglets selected in a conventional farrow-to-finish herd free from PRRSV circulation in growing pigs and sows but that maintains PRRS-1 MLV mass vaccination of sows with Porcilis PRRS (MSD, Beaucouzé, France) in order to keep a certain level of immunity in case of PRRSV reintroduction in the herd. Before starting the study, the absence of PRRSV circulation was individually checked by ELISA in pigs sampled at the end of the fattening period and by PCR in weaned piglets using sample pools of 5 animals. Piglets used in this study were born from 4 sows with high PRRSV NA titres and from 5 sows with low PRRSV NA titers. At 1 woa, blood was collected from piglets in order to assign them according to their PRRSV-specific MDNA level: A+ (high level, mean NA titre 201 ± 73) and A− (low level, mean NA titre 10 ± 5). At 3 woa, study piglets were weaned, transferred to the Anses biosafety level 3 animal facilities in Ploufragan and randomly distributed according to A+/A− status, weight and gender (Fig. 1; 8 piglets per group). The absence of PRRSV infection in piglets at 3 woa was checked by RT-PCR using sample pools of 5 animals. The decay of MDA was then individually evaluated at 3 woa afterwards (A+: mean NA titre 10 ± 5; A−: no-longer detectable NA). Piglets were vaccinated (V+) or not (V−) twice at 3 and 4 woa using one dose of Porcilis PRRS vaccine (MSD, Beaucouzé, France) by intramuscular injection in the neck using a syringe with a needle 0.6 × 25 mm (vaccine lot No. A208DB01). At 5 weeks post-first vaccination (W5 pv), half of the piglets were inoculated with 5.10⁵ TCID₅₀/pig of the PRRSV-1 Finistere strain (PRRS-FR-2005-29-24-1) by nasal inoculation using a syringe without needle (2.5 mL per nostril). The day after, non-inoculated contact (C) piglets of the same immune status were mingled with inoculated (I) piglets in the same pens (2 C and 2 I piglets by pen). Eight unvaccinated and non-inoculated piglets (4 A+ and 4 A−) were assigned to control groups. Due to the waning of MDNA, at the time of PRRSV inoculation the A+ piglets from the V−/C0 and control groups had undetectable PRRS antibody levels (VNT and ELISA tests, data not shown). This identical immune status between A+ and A− allowed us to mingle the results of the A+ and A− piglets from V− and control groups for the post-inoculation period.

Blood samples were collected from the jugular vein once a week for 5 weeks pv to individually detect viremia and monitor humoral and cellular immune responses. After challenge, clinical signs were recorded daily and blood was collected twice a week until animals were euthanized at day 42 post-inoculation (D42 pi) to individually quantify the Finistere strain viremia and to evaluate the immune response. All experiments were authorized by the French...
Ministry for Research (project No. APAFIS#3694-2016012009236
491_v5) and approved by the national ethics committee number 16.

2.2 Virus neutralization test

PRRSV-specific NAs were quantified in serum on MARC145 cells
targeting the vaccine strain, as previously described [14].

2.3. RT-PCR

Before challenge, the vaccine strain genome was detected using the
Adiavet™ PRRS real-time RT-PCR kit (Adiagene, Saint-Brieuc,
France). After challenge, specific detection of the Finistere strain
genome was assessed by qRT-PCR, as described by Rose et al. [8].

2.4. ELISPOT

PRRSV-specific IFNg-secreting cells (IFNg-SCs) were quantified
as previously described [14], using 16 h PRRSV stimulation of
4 × 10^5 PBMCs with a multiplicity of infection of 0.2 for either
the vaccine strain or the Finistere strain. The number of spots per
well was counted using an ImmunoSpot S5 UV Analyzer (CTL, Sha-
ker Heights, OH, USA).

2.5. ELISA

Antibodies against PRRSV were detected in serum using PRRS
X3 Ab ELISA tests (IDEXX laboratories, Liebefeld, Switzerland).
Sample-to-positive (S/P) ratios with values equal to or greater than
0.4 were considered positive.

Porcine IFNa was quantified in serum using an in-house ELISA
test, as previously described [16].

2.6. Statistical analysis

All the data and calculated areas under the curve (AUCs) were
compared between groups using the Kruskal–Wallis test
(p < 0.05). Post hoc pairwise comparisons were then performed
using the Holm test to adjust the p-values of these comparisons
according to the number of tests conducted (p < 0.05). The relation-
ship between the blood genomic viral load and the number of
IFNg-SCs for all the inoculated animals during the post-challenge
follow-up period was assessed with a Spearman correlation test
(p < 0.05).

The estimation of the transmission parameters was based on a
SEIR model, where each individual was considered according to the
virological results as susceptible (uninfected), exposed (infected
without virus excretion), infectious (infected with virus excretion)
or removed (protected without a role in the infectious process).

The duration of the latency period and the transmission rate of
the virus were estimated by Bayesian inference using the
Metropolis-Hastings algorithm, as previously used [8]. Conver-
gence was assessed by visual inspection and diagnostic tests
(Gelman–Rubin, autocorrelation, Heidelberger).

3. Results

3.1. MDNAs reduce PRRS immunization in vaccinated piglets

At W1 pv, the vaccine strain was detected in only 2 out of 16
A–V+ piglets (Fig. 2A). A second vaccination was thus performed
at W1 pv in the same conditions as the first. At W2 pv, 11 out of
16 A–V+ piglets (68%) were viremic, whereas only 1 out of 16 (6%)
were so in the A+V+ piglets. The difference between A+V+ and
A–V+ was maintained until W5 pv, with two-fold fewer viremic
piglets in A+V+ compared to A–V+ piglets (Fig. 2A). A significant
IFNg response was observed at W3 pv and W5 pv for A–V+ piglets,
whereas for the A+V+ group, the number of IFNg-SCs was only sig-
nificantly increased at W3 pv (Fig. 2B). Regarding the seroconvert-
sion, all A–V+ piglets except one showed a detectable PRRSV
antibody level in serum at W5 pv (Fig. 2D), while at the same time,
only 7 out of 16 A+V+ piglets were seropositive (Fig. 2C).

3.2. MDNAs reduce PRRS vaccine efficacy in challenged piglets

After PRRSV challenge, very mild clinical signs were observed.
Unvaccinated inoculated (V–I) piglets showed a significant raise
of rectal temperature at 3, 8 and 9 days post-challenge compared
to unchallenged control piglets but no statistical difference was
observed in growth performance (Supplementary Fig. 1). In the
vaccinated inoculated pigs, whatever their MDNA status (A+V+ and
A+V–I), no significant difference was observed with the V–I
group for rectal temperature nor growth performance.

A lower Finistere strain viral load was detected for A–V+ pig-
lets compared to V–I animals (AUC = 21.8 log10 equivalent TCID50/
ml * week ± 7.8 and 53.0 log10 equivalent TCID50/ml * week ± 4.7
respectively; p = 0.003), with 100-fold lower values at D10 pi
(p = 0.019) (Fig. 3A). No difference was observed between the A
+V+I and V–I groups, or between vaccinated groups. Mean viremia
duration was shortened from 21 ± 6 days for V–I or 21 ± 7 days for
A+V+I to 16 ± 9 days for A–V+ animals, but not significantly.

Vaccination induced an early IFNg response against the Finis-
tere strain at D7 pi in inoculated piglets for both the A–V+ and
A+V+ groups (Fig. 3B). Even though more IFNg-SCs were detected
in A+V+ piglets compared to A+V+I piglets, the difference was not signif-
ificant. Interestingly, considering all inoculated pigs during the D7–
D15 pi period, a negative correlation could be established between
the number of IFNg-SC and the Finistere strain genomic load in
serum (r = −0.55; p < 0.05). NAs were detected from D30 pi in in-
oculated pigs. At D42 pi, 6 out of 8 A–V+ I pigs had quantifiable
NAs titres (>10) compared to 3 out of 8 for A+V+I and 1 out of 8
in V–I animals (Supplementary Fig. 2).

3.3. MDNAs impair vaccine reduction of PRRSV transmission

A reduction in viremia was observed in A–V+ C contact pigs
compared to V–C piglets (AUC = 30.3 log10 equivalent TCID50/
ml * week ± 15.5 and 56.9 log10 equivalent TCID50/ml * week ± 10.3
respectively; p = 0.002), but not in A+V+C piglets (Fig. 3C). At D7 pi, the Finistere strain was not yet detected in A–V+
C piglets, whereas the first positive piglets were identified at D4
pi in the other contact groups (Fig. 3D). The mean viremia duration
for A–V+C was shortened to 6 ± 3 days compared to 12 ± 6 and
19 ± 6 days for the A+V+C and V–C groups, respectively. The Finis-
tere strain was detected in all unvaccinated pigs. In vaccinated
groups, all the contact animals became infected, except one A+V+
C pig (Fig. 3D).

The A+V+C pig that remained uninfected had seroconverted
post-vaccination. Considering this outlier animal as protected
against PRRSV infection with no role in the transmission process,
the estimates for the transmission rate of the A+V+ group was
comparable to those of the V– group (0.44 [0.18; 1.76] and 0.32
[0.14; 0.68] for A+V+ and V– respectively; Table 1). For the A–V+
group, the estimated transmission rate was reduced to 0.15
[0.07; 0.29].

3.4. High IFNa level was present at the time of the first vaccination

In order to understand the unexpectedly low vaccine viremia
detected in A– piglets after the first vaccination, the IFNa level
was assessed in serum samples collected at W0 pv during the present experiment (Experiment B) and compared with those collected at the same time during our previous study [14] (Experiment A) where the vaccine viremia was detected in most of the A+ animals after vaccination. The results showed significantly higher levels of IFNa for piglets in Experiment B than for those in Experiment A (Fig. 4A). A relationship could be thus hypothesized between high IFNa levels detected at the time of vaccination and low subsequent vaccine strain detection (Fig. 4B).

**4. Discussion**

Vaccination programs hardly eradicate PRRSV circulation in farms whereas PRRS MLV showed a good efficacy in piglets to control PRRSV transmission in experimental conditions [5,8]. In a previous study, we demonstrated an interference of MDNAs on post-vaccine immune responses induction during 4 weeks post-vaccination, suggesting a negative impact of MDNAs on vaccine efficacy in piglets [14]. To test this hypothesis, PRRSV-1 MLV vaccinated piglets with low or high levels of MDNAs were challenged with a field PRRSV-1 strain.

Despite the animals had to be vaccinated twice in the present study, vaccine viremia was detected in only one A+V+ piglet whereas it was detected in 11 A−V+ piglets at W2 pv, which was in accordance with our previous data [14] and confirmed the interference of MDNAs with vaccine viremia. This experiment also indicated that in piglets with low levels of MDNAs, vaccination induced significant humoral and cellular post-vaccine immune response, which also corroborates our previous results [14].

In the present study, we observed a lower interference of MDNAs on post-vaccine immune responses compared to the previous one reported by Fablet [14] where a complete impairment was observed during 4 weeks pv. This reduced interference could be ascribed to the need to vaccinate the piglets twice and the ensuing decrease of MDNA levels at the time of the second vaccination. At the time of first vaccination (3 woa), the decrease of MDNA level was already high but the mean NA titre in the present study (10 ± 5) was comparable to the one in Fablet’s study (20 ± 15). Despite the slightly reduced post-vaccine differences between A+V+ and A−V+ we observed in the present study, the post-challenge results demonstrated for the first time that the PRRSV vaccination was effective only in piglets with low levels of MDNAs. The low virulence of the PRRSV-1 strain used to challenge the animals limited the evaluation of the vaccine efficacy to virological parameters only. We previously demonstrated that the Porcilis PRRS vaccine can protect SPF piglets (no MDAs) from a challenge with the same low virulent strain, decreasing the viremia in inoculated piglets and considerably reducing the transmission of the Finistere strain to contact piglets [8]. In the present study, the challenge strain viral load was significantly reduced only in A−V+ inoculated and contact piglets compared to unvaccinated piglets. In a similar unpublished study, we also showed that PRRSV challenge strain viremia was significantly reduced for A−V+ inoculated
piglets compared to A+V+ animals during the first 3 weeks pi (Supplementary Fig. 3). In this study, vaccine viremia was also only detected in 1 out of 12 A/C0V+ piglet at W2 post-vaccination but a second vaccination was not performed before challenge, indicating that the negative impact of MDNAs on PRRS vaccine efficacy also occurred in the absence of vaccine viremia and with usual single vaccination protocols implemented in the field.

Using a closely-related approach, Jeong et al. evaluated the efficacy of a PRRSV-2 MLV vaccine in 1-day-old piglets with maternally-derived antibodies (MDAs) but no impact of MDAs was observed [17]. In Jeong’s study, all the piglets were MDA+ at vaccination (no MDA- group included) and thus this precluded to clearly evaluating the impact of MDAs on the vaccine efficacy. As the same, Balasch et al. recently showed that vaccination of 1-day-old piglets using a new PRRSV-1 MLV in presence of MDAs induced a partial protection against a challenge at 67 days pv [18]. In Balasch’s study, NAs were quantified in piglets at the vaccination time but here also the absence of comparison with vaccinated piglets without MDNAs limits the conclusions of the study.

The interference of MDAs on vaccine efficacy was previously demonstrated for many other swine diseases. Using a killed vaccine against porcine circovirus type 2, a similar study comparing vaccine efficacy in piglets with low or high MDA levels showed a significant reduction of percentage of PCR positive animals in A/C0V+ group compared to A+V+ group at 22 days post-challenge [19]. Using a MLV against classical swine fever, 83% of piglets with high MDNA levels at vaccination died from a challenge at 10 weeks of age, whereas all piglets with low MDNA levels, survived from the challenge [20].

In addition, considering the contact animals, our results also demonstrated that MDNAs decreased the PRRS vaccine efficacy on virus transmission. In the present study, PRRS vaccination in A–V+ piglets reduced the transmission rate of the Finistere strain two-fold compared to the rate estimated for the V- group. The magnitude of the effect is substantially lower than what was found in our previous study with a ten-fold reduced transmission rate in vaccinated SPF pigs, with non MDA [8]. One possible explanation for this discrepancy may be the intradermal route (ID) used for vaccination in our previous work. This immunization route was previously shown to induce an enhanced cell-mediated immune

Table 1

| Transmission parameters estimation. | Transmission rate | Latency duration* |
|------------------------------------|------------------|------------------|
|                                    | Median | 95% CI       | Median | 95% CI       |
| A–V+                               | 0.15   | [0.07; 0.29]  | 1.94   | [1.19; 2.93]  |
| A+V+                               | 0.44   | [0.18; 1.76]  | 2.00   | [1.38; 2.92]  |
| V–                                 | 0.32   | [0.14; 0.68]  | 0.99   | [0.14; 1.84]  |

* A+V+ group considering the uninfected pig as protected.

* Days of latency duration.

* 95% credibility interval.

Fig. 3. Post-inoculation data. (A) Quantification of PRRSV Finistere strain genome load by qRT-PCR in serum collected from inoculated piglets, or (C) in contact piglets. Different letters (a, b, c) indicate that the groups are significantly different from each other with p < 0.05. (B) Count of IFNg secreting cells (IFNg-SCs) responding to an in vitro Finistere strain stimulation among PBMCs purified from blood of inoculated piglets. All data are reported as the mean ±SD of results obtained from piglets in each group (n = 8 in each group). Different letters (a, b, c) indicate that the groups are significantly different from each other, with p < 0.05. (D) Serum detection of PRRSV Finistere strain genome by qRT-PCR for each contact piglet. Grey areas: positive detection; White areas: negative detection.
in our A kinase could be responsible for the inhibition of vaccine replication in our previous study [14] and in the same range as the concentration from the present study at 3 woa were much higher than those from shown to be able to completely inhibit PRRS MLV replication [22].

We detected IFNa as strongly inhibiting the replication displayed in A kinase after the first vaccination. To explore these unexpected results, we attempted to investigate the origin of this low vaccine replication in A–V+ piglets after vaccination at 3 woa. The vaccine strain was strained, but no problem was detected. As IFNa was recently shown to strongly inhibit the replication of a genotype 2 PRRS MLV [21], we hypothesized this cytokine could be responsible for the inhibition of vaccine replication in our A–V+ piglets. Indeed, the levels of IFNa detected in piglets from the present study at 3 woa were much higher than those from our previous study [14] and in the same range as the concentration shown to be able to completely inhibit PRRS MLV replication [22].

To bring some preliminary conclusions, it seems that IFNa concentrations likely to interfere with PRRS MLV replication could be achieved in piglets under field conditions. In the absence of suitable samples (not of the right type or not collected at the right time) for further exploration, we were not able to identify the cause of these increased IFNa levels. However, this cytokine is known to be produced in response to many viral infections such as swine influenza [23] or porcine respiratory coronavirus [24,25] that could infect piglets at weaning when they are frequently vaccinated against PRRSV. As a result, this potential viral interference with the PRRS MLV vaccine may be another possible explanation for the limited PRRS MLV vaccine efficacy observed in the field.

5. Conclusions

Our results confirm that MDNAs impair PRRS vaccine strain replication and post-vaccination immune response. Furthermore, we demonstrated for the first time that this impaired immune response results in decreased vaccine efficacy based on virological parameters evaluation after a low virulent PRRSV challenge. The use of a more virulent strain for the challenge of the animals may bring further clinical arguments regarding the reduced vaccine efficacy in presence of high levels of MDNAs. Unexpectedly, we also showed that other factors such as IFNa may interfere with PRRS MLV vaccination. Further research is needed to explore a possible viral interference phenomenon toward PRRS MLV vaccines. At the end, the low efficacy of PRRS vaccination observed in the field could thus result from endogenous (MDAs) as well as exogenous (viral infection) factors.

Acknowledgements

The authors are grateful to Virginie Dorenlor, Eric Eveno and Florent Eono for their involvement in pig sampling in the field. We are also thankful to Sophie Mahé and Mireille Le Dimna for their contribution to sample analysis. We thank Yann Bailly and Gerald Le Diguerher for animal care and Jennifer Richardson from the Anses-Inra-ENVA Virology laboratory for access to the Elispot reader. This work was supported by the European PRRS Research Award 2015, the “Conseil Régional de Bretagne” and the “Union des Groupements de Producteurs de Viande de Bretagne”.

Author contributions

PR analyzed the samples, interpreted the results and drafted the manuscript. CF participated in the design of the experiment, coordinated the study at the farm, and performed the statistical analyses. MA developed the mathematical model and participated in the data analyses. VN and AL identified the study farm. FP coordinated the animal experiments. NR participated in the design of the study. OB designed the study, supervised the analyses, and interpreted the data. All co-authors revised the manuscript and approved the final submitted version.

Declaration of Competing Interest

The authors state that they have no conflict of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found in the online version, at https://doi.org/10.1016/j.vaccine.2019.06.045.
References

[1] Dokland T. The structural biology of PRRSV. Virus Res 2010;154:86–97. https://doi.org/10.1016/j.virusres.2010.07.029.

[2] Neumann EJ, Kliebenstein JB, Johnson CD, Mahy JW, Bush EJ, Seitzinger AH, et al. Assessment of the economic impact of porcine reproductive and respiratory syndrome on swine production in the United States. J Am Vet Med Assoc 2005;227:385–92.

[3] Nathues H, Alarcón P, Rushton J, Jolie R, Fiebig K, Jimenez M, et al. Cost of porcine reproductive and respiratory syndrome virus at individual farm level – An economic disease model. Prev Vet Med 2017;142:16–29. https://doi.org/10.1016/j.prevetmed.2017.04.006.

[4] Fablet C, Marois-Crehan C, Simon G, Gasland B, Jestin A, Kobisch M, et al. Infectious agents associated with respiratory diseases in 125 farrow-to-finish pig herds: a cross-sectional study. Vet Microbiol 2012;157:152–63. https://doi.org/10.1016/j.vetmic.2011.12.015.

[5] Martelli P, Gozio S, Ferrari L, Rosina S, De Angelis E, Quintavalla C, et al. Efficacy of a modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in pigs naturally exposed to a heterologous European (Italian cluster) field strain: Clinical protection and cell-mediated immunity. Vaccine 2009;27:3788–99. https://doi.org/10.1016/j.vaccine.2009.03.028.

[6] Mürtaug MP, Genzow M. Immunological solutions for treatment and prevention of porcine reproductive and respiratory syndrome (PRRS). Vaccine 2011;29:8192–204. https://doi.org/10.1016/j.vaccine.2011.09.013.

[7] Prieto C, Alvarez E, Martínez-Lobo FJ, Simarro I, Castro JM. Similarity of European porcine reproductive and respiratory syndrome virus strains to vaccine strain is not necessarily predictive of the degree of protective immunity conferred. Vet J 2008;175:356–63. https://doi.org/10.1016/j.tvjl.2007.01.021.

[8] Rose N, Renson P, Andraud M, Paboeuf F, Le Potier MF, Bouriou O. Porcine reproductive and respiratory syndrome virus (PRRSV) modified-live vaccine reduces virus transmission in experimental conditions. Vaccine 2015;33:2493–9. https://doi.org/10.1016/j.vaccine.2015.03.040.

[9] Pietri E, Gibert E, Soldevila F, García-Saenz A, Pujados J, Diaz I, et al. Vaccination with a genotype 1 modified live vaccine against porcine reproductive and respiratory syndrome virus significantly reduces viremia, viral shedding and transmission of the virus in a quasi-natural experimental model. Vet Microbiol 2015;175:7–16. https://doi.org/10.1016/j.vetmic.2014.11.007.

[10] Alexopoulos C, Kritas SK, Kyriakis CS, Tzika E, Kyriakis SC. Sow performance in conditions of high interferon titer in newborn pig intestine. J Vet Med A 2015;62:1805–11. https://doi.org/10.1196/annals.1373.014.

[11] Geldhof MF, Van Breedam W, De Jong E, Lopez Rodriguez A, Karniychuk UU, et al. Antibody response and maternal immunity upon boosting PRRSV-immune sows with experimental farm-specific and commercial PRRSV vaccines. Vet Microbiol 2013;167:260–71. https://doi.org/10.1016/j.vetmic.2013.08.017.

[12] Lopez OJ, Oliveira MF, Garcia EA, Kwon BJ, Doster A, Osorio FA. Protection against porcine reproductive and respiratory syndrome virus (PRRSV) infection through passive transfer of PRRSV-neutralizing antibodies is dose dependent. Clin Vaccine Immunol 2007;14:269–75. https://doi.org/10.1128/cvi.00304-06.

[13] Loving CL, Osorio FA, Murtaslaugh MF, Zuckermann FA. Innate and adaptive immunity against porcine reproductive and respiratory syndrome virus. Vet Immunol Immunopathol 2015;167:1–14. https://doi.org/10.1016/j.vetimm.2015.07.003.

[14] Fablet C, Renson P, Enoo F, Mahe S, Eveno E, Le Dimna M, et al. Maternally-derived antibodies (MDAs) impair piglets’ humoral and cellular immune responses to vaccination against porcine reproductive and respiratory syndrome (PRRS). Vet Microbiol 2016;192:173–80. https://doi.org/10.1016/j.vetmic.2016.07.014.

[15] Balka G, Dreckmann K, Papp G, Kraft C. Vaccination of piglets at 2 and 3 weeks of age with Ingelvac PRRSFLEX® (R): EU provides protection against heterologous field challenge in the face of homologous maternally derived antibodies. Porcine Health Manag 2016;2:24. https://doi.org/10.1016/j.shpm.2016.03.007.

[16] Jamin A, Gorin S, Le Potier MF, Kuntz-Simon G. Characterization of conventional and plasmacytoid dendritic cells in swine secondary lymphoid organs and blood. Vet Immunol Immunopathol 2006;114:224–37.

[17] Jeong J, Kim S, Park KH, Kang I, Park SJ, Yang S, et al. Vaccination with a porcine reproductive and respiratory syndrome virus vaccine at 1-day-old improved growth performance of piglets under field conditions. Vet Microbiol 2018;214:113–24. https://doi.org/10.1016/j.tvjl.2017.12.023.

[18] Balasch M, Fort M, Taylor LP, Calvert JC. Vaccination of 1-day-old pigs with a porcine reproductive and respiratory syndrome virus (PRRSV) modified live attenuated virus vaccine is able to overcome maternal immunity. Porcine Health Manag 2018;4:25. https://doi.org/10.1186/s40813-018-0101-x.

[19] Feng H, Segales J, Fraile L, Lopez-Soria S, Sibila M. Effect of high and low levels of maternally derived antibodies on porcine circovirus type 2 (PCV2) infection dynamics and production parameters in PCV2 vaccinated pigs under field conditions. Vaccine 2016;34:3044–50. https://doi.org/10.1016/j.vaccine.2016.04.088.

[20] Vandeputte J, Tso HT, Ng FK, Chen C, Chai KK, Liao GA. Adsorption of collostral antibodies against classical swine fever, persistence of maternal antibodies, and effect on response to vaccination in baby pigs. Am J Vet Res 2001;62:1805–11.

[21] Brockmeier SL, Loving CL, Eberle KC, Hau SJ, Buckley A, Van Geelen A, et al. Treatment with interferon-alpha delays disease in swine infected with a highly virulent CSFV strain. Virology 2001;267:125–35. https://doi.org/10.1006/viro.2000.1078.

[22] Fablet C, Renson P, Eono F, Mahe S, Eveno E, Le Dimna M, et al. Maternally-derived antibodies against classical swine fever, persistence of maternal antibodies, and effect on response to vaccination in baby pigs. Am J Vet Res 2001;62:1805–11.

[23] Fernández-Sanz I, Ramañonan P, O'Donnell V, Dreckmann K, Papp G, Kraft C. Vaccination of piglets at 2 and 3 weeks of age with Ingelvac PRRSFLEX® (R): EU provides protection against heterologous field challenge in the face of homologous maternally derived antibodies. Porcine Health Manag 2016;2:24. https://doi.org/10.1016/j.shpm.2016.03.007.